Loading...
Header Logo
Keywords
Last Name
Institution

MICHAEL KA KEU WONG

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Methods for Monitoring of the Anti-Angiogenic Activity of Agents in Patients. 341-359.
    2. Melanoma biology. Community Oncology. 5:6-13.
    3. Erratum. American Journal of Clinical Oncology: Cancer Clinical Trials. 28:455.
    4. Erratum. Cancer Research. 61:5956.
    5. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma. ONCOLOGY (United States). 27.
    6. Ultrasound contrast microbubbles targeted to tumor angiogenesis specifically bind tumor-derived endothelial cells. Unknown Journal. 2:897-898.
    7. Investigating a new entubulation strategy to overcome peripheral nerve injury. 751-752.
    8. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 1-12.
    9. Review of US comparative economic evidence for treatment of metastatic renal cell carcinoma after failure of first-line VEGF inhibitor therapy. American Health and Drug Benefits. 6.
    10. The role of tissue culture in oncology research. Current Oncology. 5:67-69.
    11. The genetic study of cells. Current Oncology. 5:4-8.
    12. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy. Clinical Genitourinary Cancer.
    13. Implementation of an Interleukin-2 National Registry. Journal for ImmunoTherapy of Cancer. 2.
    14. Erratum. Cancer Research. 61:4297.
    Same Department Expand Description